`J7645` Ipratropium bromide comp

Ipratropium bromide, inhalation solution, compounded product, administered through dme, unit dose form, per milligram

Medicare coverage: Carrier judgment
Status: active (October 2026 file)

Medically Unlikely Edits (effective October 1, 2026)

Practitioner: max 0 units per day (clinical), rationale: Compounded Drug Policy
Outpatient hospital: max 0 units per day (clinical), rationale: Compounded Drug Policy
DME supplier: max 0 units per day (clinical), rationale: Compounded Drug Policy

Medicare pricing for J7645

Physician Fee Schedule (CY 2026, RVU26D)

Status E: excluded from the PFS by regulation.

Payer policies and prior authorization for J7645

Payer coverage policies that name J7645

J7645 appears in 5 coverage policies from Aetna.

Payer	Policy	Role in policy	Reviewed	Document
Aetna	Depemokimab-ulaa (Exdensur) (1098)	listed, no stance	Aug 10, 2026	payer document
Aetna	Nebulizers (0065)	covered if criteria are met	Mar 18, 2026	payer document
Aetna	Omalizumab (0670)	listed, no stance	Aug 21, 2026	payer document
Aetna	Reslizumab (Cinqair) (0907)	listed, no stance (range J7644-J7645)	Aug 10, 2026	payer document
Aetna	Tezepelumab-ekko (Tezspire) (1003)	listed, no stance (range J7644-J7645)	Aug 6, 2026	payer document

Medicaid fee-for-service

Prior authorization required or conditional in IN.

KS: $1.13 (default), effective Jan 1, 2007
OH: $0.23 (provider_administered_drugs), effective Sep 1, 2013
VT: $0.00 (outpatient_hospital_opps), effective Feb 1, 2026
WY: $0.00 (outpatient_hospital_apc, Children's Hospitals), effective Apr 1, 2026

From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.

J7645 Ipratropium bromide comp